Clinical and Economic Impacts of a Commercial
Vaccine Containing Recombinant Antigen against Atrophic Rhinitis in
Field Conditions
Myung Hyee Kim1,2, Sung J. Yoo1,
Taeyong Kwon1, Sang H Jae1, Dong-Uk Lee1,
Jeongjae Byun1, Jeongyeon Shin1, Sang won Seo1,2and Young S Lyoo1,*
1College
of Veterinary Medicine, Konkuk University, 120 Neungdong-ro,
Gwangjin-gu, Seoul 05029, South Korea;
2Hipra
Korea, Inc., 262 Hwangsaeul-ro, Bundang-gu, Seongam-si, Gyeonggi-do
13557, South Korea *Corresponding author: lyoo@konkuk.ac.kr
Abstract
Atrophic rhinitis (AR) is an important disease
continuously causing economic losses to pig industry. Due to the detrimental
effects on growth performance, antibiotics have been widely used to treat the
bacterial diseases in the field. As the concerns about bacterial resistance to
antibiotics increase, there is a growing need for the evaluation of AR vaccine
that can reflect actual cost and benefits. However, until now, only limited
research data have been available. Therefore, in this study, the systemic
analyses of clinical and economic benefits by AR vaccination under field
conditions were conducted. The trials were performed using a bivalent commercial
vaccine containing Bordetella
bronchiseptica bacterin and recombinant Type D
Pasteurella multocida toxin in three
different commercial pig farms endemic for AR. Significant higher levels of
colostral antibodies and those passive transfer were detected from vaccinated
sows to their offspring compared to non-vaccinated groups. As predicted on
serological data, notably better clinical protection from the deleterious
effects of AR was identified in piglets born to the vaccinated sows based on
body weight, rearing period, and gross nasal scores. Moreover, vaccination on
sows delivered a return on investment at least ten times the cost of
vaccination. Collectively, these favorable clinical and economic effects in the
commercial farms sufficiently support the necessity and significance of AR
vaccination on sows.
To Cite This Article: Kim MH, Yoo SJ, Kwon T, Jae SH, Lee DU, Byun J,
Shin J, Seo SW and
Lyoo YS, 2018. Clinical and economic impacts of a
commercial vaccine containing recombinant antigen against atrophic rhinitis in
field conditions. Pak Vet J, 38(4): 394-398. http://dx.doi.org/10.29261/pakvetj/2018.074